Companion Diagnostics & Biomarkers 2017


The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers 2017 . This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.

Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner.

Companion Diagnostics & Biomarkers 2017 you will provide valued information about doing partnership and commercialize CDx tests with pharmaceutical and biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.

We sincerely hope you are able to join us for this year’s meeting and be part of a new paradigm of precision medicine at the Companion Diagnostics & Biomarkers 2017



  • Learn the recent advances and future perspectives in Companion Diagnostics & Biomarkers
  • Understand the key aspects & challenges of Clinical Biomarker development & qualification Solutions for clinical development of precision therapies
  • Regulatory considerations for Next Generation Sequencing (NGS)
  • Main barriers to progression of precision medicine in drug development
  • The Role of In Vitro Diagnostics in Successful Precision Medicine Market Access
  • Options for biomarker based patient stratification in NON-ONCOLOGY clinical development Key trends in targeted and immuno-oncology companion diagnostics
  • Overcoming challenges in the global commercialization of novel biomarkers Diagnostic Strategies for Cancer Immune Therapies
  • Strategic Partnerships for CDx – Challenges and Opportunities



The BioTech Pharma Summit (EPM Group) are exclusive events designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed mem- bers of academic and government institutions.
Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

  • Companion Diagnostics
  • Molecular Diagnostics
  • Personalized Healthcare
  • Clinical Development
  • Regulatory Affairs
  • Molecular Diagnostics
  • Biomarkers
  • Medical Sciences
  • Experimental Medicine
  • Translational Medicine
  • Immunology
  • Genomics
  • Insurers
  • Patient Advocates
  • Payers
  • Market Access
  • Medical Sciences
  • Commercialisation
  • Oncology
  • Non-oncology
  • Rare Diseases
  • Drug Development
  • Research
Chief Business Officer at HistogeneX, US
Managing Director at Martina Kaufmann Strategic Consulting, DE
Managing Director at Unilabs Denmark
Director Business Development at Thermo Fisher Scientific, DE
Vice President Product and Business development at SpinChip Diagnostics
Cancer Research UK Professor at the University of Manchester
General Manager & Partner at fundamenta Life Science GmbH.
Vice President of Regulatory Affairs at Guardant Health
CEO at oncgnostics
Executive Vice President, Commercial Operations at SkylineDx
Vice President, Emerging Technologies at Precision for Medicine
CEO, Sr. Executive, Board Director, Author, MoneyBall Medicine & Commercialization of Novel IVDs​
Chairman and CEO at QIAGEN (Suzhou) Translational Medicine Co. Ltd.
Vice President, Discovery Research at hVIVO
Managing Director at Novateur Ventures Inc.
Senior Vice President, Precision Diagnostics at Immunovia AB
Global Commercial Director, CDx Commercial Management at Agilent Technologies
Vice President, Precision and Transformative Technology Solutions at Evidera
Relationship and Alliance Management at Hologic
Partner, Personalized Medicine at Health Advances
SVP Product Strategy & Partner Integration at Treato & Product Advisor at Neurolex Diagnostics
Document Package
Buy Ticket

Access to all event presentations

*Subject to speaker's approval for distribution